Skip to content

Dim Light at Night in Patients With Obstructive Sleep Apnea

Effects of Sleeping With Dim Light at Night in Patients With Obstructive Sleep Apnea

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01853891
Enrollment
0
Registered
2013-05-15
Start date
2013-02-28
Completion date
2018-06-01
Last updated
2025-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea (OSA)

Brief summary

With the advent of electricity, light at night has become a ubiquitous part of our society. The main purpose of this study is to determine whether sleeping with dim light (40 lux), the brightness of a night light) in your bedroom for 5 consecutive nights will result in increased markers of inflammation in the blood compared to sleeping in darkness during the night in patients with obstructive sleep apnea (OSA). A secondary aim is to examine the effects on insulin sensitivity, other blood proteins, and RNA molecules as a result of sleeping with dim light. RNA molecules are substances in blood that dictate what type of proteins the body should make.

Detailed description

The primary objective of this study is to determine whether sleeping with dLAN (40 lux) for 5 consecutive nights will result in increased markers of inflammation compared to sleeping in darkness (\< 1 lux) during the night in patients with OSA. A secondary aim is to examine the effects on insulin sensitivity, adipokines, and RNA molecules. The risks associated with this study are minimal compared to the potential benefits. Knowledge about the effects of sleeping with dim light on inflammation in patients with OSA is important and would guide future recommendations about proper sleep hygiene. This research may also guide future recommendations about light conditions in other environments such as hospital bedrooms.

Interventions

OTHERdim light at night

Sponsors

Ulysses Magalang MD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* • 18 -60 years of age. * Willing and able to give informed consent * AHI \>10 episodes per hour based on a prior PSG. * Patients who have been started on treatment for OSA with either Continuous Positive Airway Pressure (CPAP) or dental device will be eligible for the study as long as they have been compliant with treatment for at least 30 days.

Exclusion criteria

* • Incapable of giving informed consent * Under the age of 18 * Currently sleeping with lights on in the bedroom * Excessive alcohol consumption * Excessive alcohol use is defined as: * More than 3 glasses of wine a day * More than 3 beers a day * More than 60 mL of hard liquor a day * Room air oxyhemoglobin saturation \< 88% * Use of home oxygen * Use of corticosteroids and other immunosuppressive medications. * Diagnosis of: HIV, Connective Tissue Disease (Lupus, Rheumatoid arthritis), Inflammatory Bowel Disease.

Design outcomes

Primary

MeasureTime frameDescription
Exposure to Dim Light at Night5 consecutive nightsThe main purpose of this study is to determine whether sleeping with dim light (40 lux), the brightness of a night light) in your bedroom for 5 consecutive nights will result in increased markers of inflammation in the blood compared to sleeping in darkness during the night in patients with obstructive sleep apnea (OSA).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026